Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BRAF L597S |
Therapy | TAK-733 |
Indication/Tumor Type | melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF L597S | melanoma | predicted - sensitive | TAK-733 | Case Reports/Case Series | Actionable | In a Phase I trial, TAK-733 treatment resulted in a partial response after 2 cycles in a patient with metastatic melanoma harboring BRAF L597S, who remained progression-free for over 24 weeks (PMID: 22798288). | 22798288 |
PubMed Id | Reference Title | Details |
---|---|---|
(22798288) | BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. | Full reference... |